Gemcitabine in the Treatment of Relapsed and Refractory Hodgkin’s Disease
- 1 October 2005
- journal article
- clinical trial
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 28 (11), 567-571
- https://doi.org/10.1159/000088621
Abstract
Patients with refractory Hodgkin's disease or relapsing after high-dose therapy and autografting have a poor prognosis. Here, we present our experiences with gemcitabine in this setting. We treated 14 patients with relapsed or refractory Hodgkin's disease with gemcitabine. The treatment was given on a compassionate use basis, off-label and not according to a study protocol. Patients were 17-46 years of age. 1 patient had stage IA disease, 2 patients had stage IIIB disease and 11 patients had stage IVB disease. 9 patients had received radiotherapy. 8 patients had been autografted and 1 patient auto- and allografted. Gemcitabine was administered at a starting dose of 1 g/m(2) on days 1 and 8 every 3 weeks in combination with steroids. The median follow-up period was 10 months. Hematological toxicity grade 3-4 occurred in 12 patients leading to dose reductions. 1 patient died of neutropenic sepsis. No other non-hematological toxicities were observed. The response rate was 64% with 6 patients achieving complete remission (CR) and 3 patients partial remission (PR). The median time to treatment failure was 9 months, and survival was 11 months. Responses were seen in previously transplanted patients and in patients refractory to previous treatment. The so far longest responder has been in CR for over 68 months. Gemcitabine is an effective treatment for Hodgkin's disease. Heavily pretreated patients often require dose reductions.Keywords
This publication has 18 references indexed in Scilit:
- Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study GroupJournal of Clinical Oncology, 2004
- Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin diseaseCancer, 2003
- Involved-Field Radiotherapy for Advanced Hodgkin's LymphomaNew England Journal of Medicine, 2003
- Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup TrialJournal of Clinical Oncology, 2003
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant RegistryJournal of Clinical Oncology, 1999
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998
- GemcitabineDrugs, 1997
- Comparison Between Conventional Salvage Therapy and High-Dose Therapy With Autografting for Recurrent or Refractory Hodgkin's DiseaseBlood, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958